| Title |
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, September 2014
|
| DOI | 10.1007/s00280-014-2585-7 |
| Pubmed ID | |
| Authors |
Cong Li, Yangkui Gu, Ming Zhao, Yunfei Yuan, Fenghua Wang, Zhiqiang Wang, Wang Li, Huiyan Luo, Cui Chen, Gong Chen, Peirong Ding, Xiaojun Wu, Zhenhai Lu, Zhizhong Pan, Ruihua Xu, Youjian He, Desen Wan, Yuhong Li |
| Abstract |
To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 24% |
| Student > Doctoral Student | 2 | 10% |
| Professor | 2 | 10% |
| Student > Bachelor | 1 | 5% |
| Other | 1 | 5% |
| Other | 4 | 19% |
| Unknown | 6 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 38% |
| Social Sciences | 2 | 10% |
| Agricultural and Biological Sciences | 1 | 5% |
| Immunology and Microbiology | 1 | 5% |
| Unknown | 9 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2014.
All research outputs
#18,550,468
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#1,988
of 2,501 outputs
Outputs of similar age
#168,301
of 247,216 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#19
of 30 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,216 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.